Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Selecta Biosciences Receives $3 Million from NIH/NIDA to Develop Nicotine Vaccine for Smoking Cessation

Abstract:
Targeted Synthetic Vaccine Particles (tSVP) Offer Potential for Increased Anti-Nicotine Efficacy to Increase Success of Smoking Cessation

Selecta Biosciences Receives $3 Million from NIH/NIDA to Develop Nicotine Vaccine for Smoking Cessation

Watertown, MA | Posted on August 16th, 2010

Selecta Biosciences, Inc., a biopharmaceutical company developing synthetic nanoparticle vaccines and immunotherapies, today announced that it has been awarded a grant for $3 million from the National Institute on Drug Abuse (NIDA), an institute within the U.S. National Institutes of Health (NIH). The grant is aimed at advancing the development of an enhanced therapeutic nicotine vaccine for the treatment of smoking cessation and relapse prevention.

The $3 million grant will support the funding of a clinical drug candidate from Selecta's pipeline, and assist with advancing a nicotine vaccine from preclinical through early clinical evaluation. The award is one of a select number of grants provided nationwide by NIH under the unique BRDG-SPAN program (Biomedical Research and Development and Growth To Spur the Acceleration of New Technologies Pilot Program) which is designed to bridge the gap between R&D and commercialization for promising new medical technologies.

"We are delighted that NIDA has recognized the uniqueness and potential advantages of Selecta's synthetic therapeutic vaccines and has elected to support Selecta's tSVP nicotine vaccine, in a very competitive process, to address the enormous unmet medical need of smoking cessation," said Werner Cautreels, Ph.D., Chief Executive Officer of Selecta Biosciences. "We view a nicotine vaccine as one of our promising programs that are poised to advance into human clinical trials based on our progress with Selecta's technology platform"

Selecta's tSVP technology offers in this case a new approach to a nicotine vaccine designed to boost immune responses, or more specifically nicotine antibody titers, beyond previous technologies. Selecta's tSVP immunomodulatory nanoparticles aim to induce highly predictable immune responses, for durable effect in smoking cessation. Although previous research has shown the therapeutic potential for vaccinating against nicotine by inducing nicotine-specific antibodies, published studies with differently designed vaccines show that only a small fraction of study patients achieved anti-nicotine titers sufficient to increase smoking cessation above placebo.

####

About Selecta Biosciences
Selecta Biosciences, Inc. is a biopharmaceutical company developing first-in-class synthetic nanoparticle vaccines and immunotherapies, with the first applications focused on nanoparticle vaccines using its proprietary targeted Synthetic Vaccine Particle (tSVPô) technology. The tSVP platform enables full-integration of the key vaccine components, antigens and adjuvants, for highly-effective targeting to immune cells to produce an optimal immune response. The tSVP vaccines mimic the structure of natural pathogens with regards to size, shape and the sequence of immunological information that it delivers specifically to immune cells, thus harnessing the body's defense system to produce a robust immune response. The unique attributes of full-integration, targeting and natural structure conferred by the tSVP platform create synthetic nanoparticle vaccines that are engineered for unprecedented safety and efficacy. This novel approach enables expanded opportunities for tSVP vaccines, and the company is pursuing opportunities across a range of high unmet medical need applications, including infectious, metabolic, CNS and inflammatory diseases.

Selecta was founded in 2008 by three academic pioneers in the fields of nanotechnology and immunology: Professor Robert Langer (MIT), and Professors Omid Farokhzad and Ulrich von Andrian (Harvard Medical School). Selecta is backed by leading venture investors including, Polaris Venture Partners, Flagship Ventures, NanoDimension, OrbiMed Advisors and Leukon Investments. For more information please visit the company website at www.selectabio.com.

About Smoking Cessation
Through the use of tobacco, nicotine is one of the most heavily used addictive drugs and smoking is the leading preventable cause of disease, disability, and death in the United States. According to the CDC there are approximately 438,000 premature deaths in the U.S. per year due to smoking and approximately 38,000 lung cancer and heart disease deaths annually were attributable to exposure to secondhand smoke. Additionally, smoking costs the U.S. $97 billion dollars a year in direct healthcare costs and an additional $92 billion a year in productivity losses.

For more information, please click here

Contacts:
Gina Nugent
The Yates Network
Tel: 617-460-3579

Copyright © Selecta Biosciences

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Researchers find new way to control light with electric fields May 25th, 2017

Nanometrics Announces Retirement Plans of CEO Timothy Stultz: Dr. Stultz to Continue as Director May 25th, 2017

Nanomechanics, Inc. to Exhibit at the SEM Conference: Nanoindentation experts will attend and exhibit their instruments at the Conference and Exposition on Experimental and Applied Mechanics in Indianapolis May 25th, 2017

Three-dimensional graphene: Experiment at BESSY II shows that optical properties are tuneable May 24th, 2017

Nanomedicine

Zap! Graphene is bad news for bacteria: Rice, Ben-Gurion universities show laser-induced graphene kills bacteria, resists biofouling May 22nd, 2017

Sensors detect disease markers in breath May 19th, 2017

Oddball enzyme provides easy path to synthetic biomaterials May 17th, 2017

The brighter side of twisted polymers: Conjugated polymers designed with a twist produce tiny, brightly fluorescent particles with broad applications May 16th, 2017

Announcements

Researchers find new way to control light with electric fields May 25th, 2017

Nanometrics Announces Retirement Plans of CEO Timothy Stultz: Dr. Stultz to Continue as Director May 25th, 2017

Nanomechanics, Inc. to Exhibit at the SEM Conference: Nanoindentation experts will attend and exhibit their instruments at the Conference and Exposition on Experimental and Applied Mechanics in Indianapolis May 25th, 2017

Three-dimensional graphene: Experiment at BESSY II shows that optical properties are tuneable May 24th, 2017

Personal Care/Cosmetics

Programmable materials find strength in molecular repetition May 23rd, 2016

Common nanoparticle has subtle effects on oxidative stress genes May 11th, 2016

NRL reveals novel uniform coating process of p-ALD April 21st, 2016

New ORNL method could unleash solar power potential March 16th, 2016

Grants/Sponsored Research/Awards/Scholarships/Gifts/Contests/Honors/Records

Zap! Graphene is bad news for bacteria: Rice, Ben-Gurion universities show laser-induced graphene kills bacteria, resists biofouling May 22nd, 2017

Gas gives laser-induced graphene super properties: Rice University study shows inexpensive material can be superhydrophilic or superhydrophobic May 15th, 2017

Fed grant backs nanofiber development: Rice University joins Department of Energy 'Next Generation Machines' initiative May 10th, 2017

'Hot' electrons don't mind the gap: Rice University scientists find nanogaps in plasmonic gold wires enhance voltage when excited May 8th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project